CreatorsPublishersAdvertisers

#Myelofibrosis

patientpower.info

Behind the Scenes of an MPN Diagnosis

What is the process used by pathologists to make a diagnosis? During the progression of an MPN, when is a new diagnosis required? In this program, Patient Power co-founder and myelofibrosis patient Andrew Schorr meets with Carlos E. Bueso-Ramos, MD, PhD, hematopathologist at MD Anderson Cancer Center, to discuss what tests are used to determine an MPN diagnosis and when a review of that diagnosis is necessary.
Picture for Behind the Scenes of an MPN Diagnosis
pledgetimes.com

The MIELO-Spieghi campaign on social networks comes to life

With the first Facebook live, the campaign gets to the heart HONEY-Explain. From the Sant’Eugenio Hospital in Rome, today at 6 pm, the appointment is with the ‘Conversations about life with chronic myeloproliferative neoplasms (MPNs) over a cup of tea‘, live on the Fb page https://www.facebook.com/MieloSpieghi, dedicated to the campaign on chronic myeloproliferative neoplasms promoted by Novartis, in collaboration with Aipamm (Italian association of patients with myeloproliferative diseases) and with the patronage of Ail (Italian association against leukemia, lymphomas and myeloma) and the Mpn Advocates Network.
INTERNET
Picture for The MIELO-Spieghi campaign on social networks comes to life
Nature.com

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median age at BMT was 63 years (range, 41"“74). Conditioning regimens were reduced intensity in 54% and nonmyeloablative in 39%. Peripheral blood grafts were used in 86%. The median follow-up was 23.1 months (range, 1.6"“75.7). At 3 years, the overall survival, relapse-free survival (RFS), and graft-versus-host-disease (GVHD)-free-RFS were 72% (95% CI 59"“81), 44% (95% CI 29"“59), and 30% (95% CI 17"“43). Cumulative incidences of non-relapse mortality and relapse were 23% (95% CI 14"“34) and 31% (95% CI 17"“47) at 3 years. Spleen size ≥22"‰cm or prior splenectomy (HR 6.37, 95% CI 2.02"“20.1, P"‰="‰0.002), and bone marrow grafts (HR 4.92, 95% CI 1.68"“14.4, P"‰="‰0.004) were associated with increased incidence of relapse. Cumulative incidence of acute GVHD grade 3"“4 was 10% at 3 months and extensive chronic GVHD was 8%. Neutrophil engraftment was reported in 94% patients, at a median of 20 days (range, 14"“70). In conclusion, haplo-BMT with PTCy is feasible in patients with myelofibrosis. Splenomegaly ≥22"‰cm and bone marrow grafts were associated with a higher incidence of relapse in this study.
Picture for Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
TRENDING TOPICS
Business Insider

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

This collaboration expands HistoIndex's portfolio of fibrosis assessment outside of Nonalcoholic Steatohepatitis (NASH) and other liver diseases. The proprietary stain-free imaging technology, incorporated by Second Harmonic Generation (SHG) along with AI-based algorithms, will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.
HEALTH
martechcube.com

Geron to Host a Virtual Investor Event in November

Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET. Topics to be covered at the event, include:. The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential of imetelstat, Geron’s first-in-class telomerase inhibitor. Expansion opportunities...
MARKETS
targetedonc.com

Unmet Needs Loom for Later-Line Options in MPNs

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors. Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the...
CANCER
targetedonc.com

NCCN Congress: Hematologic Malignancies | Conferences

The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors. October 15, 2021. During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma. Expert Discusses...
CONGRESS & COURTS
onclive.com

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis. Srdan Verstovsek, MD, PhD, United Energy Resources, Inc. Professor of Medicine, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.
SCIENCE
onclive.com

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of risk stratification in myelofibrosis. Risk stratification with available scoring systems can inform whether a patient with myelofibrosis will derive a sustained...
CANCER
phillytrib.com

Cancer patients of color are less likely to be matched to bone marrow donors

When Chrissie Brown Torres was diagnosed with a rare form of leukemia called myelofibrosis in October 2020, the signs were at least a year in the making, she says. In late winter 2019, she experienced what she thought was a viral respiratory infection. With the COVID-19 pandemic picking up, she opted to treat herself at home, thinking her symptoms would eventually subside. But in July 2020, Torres still had some lingering symptoms, including a cough and shortness of breath. So she went to get checked out by a doctor.
CANCER
AboutLawsuits.com

FDA Warns Against Use of Artnaturals Hand Sanitizer Products, Due To Presence of Benzene

Federal health officials are warning consumers to immediately stop using certain “artnaturals” hand sanitizer products, after routine sample testing identified the presence of three chemicals, including benzene, which has been linked to a risk of cancer and other serious health effects. The artnaturals hand sanitizer warning was issued by the...
GARDENA, CA
ajmc.com

Ruxolitinib Has Cost-effectiveness, Survival Benefits for Myelofibrosis vs Competitors

Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis. A pair of abstracts presented at this year’s European Hematology Association 2021 Virtual Congress (EHA2021) show treatment with Jakafi (ruxolitinib; Novartis) is both...
DISEASES & TREATMENTS
onclive.com

Dr. Jamieson on Treatment Considerations in Myelofibrosis

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis. Catriona Jamieson, MD, PhD, team leader for the Division of Hematology/Oncology at UC San Diego Health Moores Cancer Center, discusses treatment considerations for patients with myelofibrosis. The treatment for patients with myelofibrosis is now starting earlier in the disease...
CANCER
pharmacytimes.com

Daily Medication Pearl: Ruxolitinib (Jakafi) for Myelofibrosis

Ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease. Ruxolitinib is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease. Dosing:. Myelofibrosis:. The starting dose of ruxolitinib is...
HEALTH
curetoday.com

Understanding the Variability of a Rare Blood Cancer

An expert discusses two primary unmet needs in myelofibrosis, current treatments and new approaches to this complex disease. More focus is needed on the development of new drugs that treat low blood counts and new therapies that eradicate the disruption to bone marrow in patients with myelofibrosis, according to an expert at Dana-Farber Cancer Institute.
CANCER
patientpower.info

Understanding Your MPN Lab Results

This series is supported by an educational grant from Incyte. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content. Ruth Fein:. Hi, everyone. Thanks for joining us today for this Answers Now series on myelofibrosis, one of the...
SCIENCE
AboutLawsuits.com

Coppertone Sunscreen Recall Issued Due to Dangerous Benzene Levels

Several lines of Coppertone sunscreen sprays are being recalled because they may contain dangerous levels of benzene, which is a chemical classified as a human carcinogen. The FDA announced the Coppertone sunscreen recall on September 30, after routine sample testing confirmed the presence of potentially unsafe levels of the benzene in several brands of aerosol spray cans intended for babies, kids and adults.
FDA
patientpower.info

Strategies to Manage Symptom Burden in Myelofibrosis

How can it be determined if a new symptom is related to myelofibrosis? What are some strategies for easing symptom burden? Lindsey Lyle, MS, PA-C, Physician Assistant and Senior Instructor at the University of Colorado Anschutz Medical Campus, explains what symptoms should be reported immediately, how to communicate with your doctor about new symptoms, and advice for dealing with the anxiety that can arise while managing the symptoms of myelofibrosis.
MENTAL HEALTH
targetedonc.com

Ali Discusses Treatment Options and Spleen Size in Primary Myelofibrosis

Case-Based Roundtable Meetings Spotlight, Case-Based Roundtable Meeting Spotlight September 2021:Hematologic Malignancies,. Haris Ali, MD, discussed a 68-year-old woman who presented to her physician with symptoms of fatigue and abdominal pain lasting 4 months; she also reported increased bruising. During a Targeted OncologyTM Case-Based Roundtable event, Haris Ali, MD, associate clinical...
CANCER
YOU MAY ALSO LIKE